In addition to the developments in vaping cessation, Oppenheimer maintains a positive outlook on the smoking cessation aspect, which remains the main value driver for the company.
The analyst anticipates a New Drug Application (NDA) submission for smoking cessation to occur in the second quarter of 2025. With these milestones on the horizon, the firm's reiterated Outperform rating and $11 price target reflect confidence in Achieve Life Sciences (NASDAQ:ACHV)' trajectory.
The stock currently carries a strong analyst consensus recommendation of 1.12, though investors should note that four analysts have recently revised their earnings expectations downward for the upcoming period.
The stock currently carries a strong analyst consensus recommendation of 1.12, though investors should note that four analysts have recently revised their earnings expectations downward for the upcoming period.
In addition to the developments in vaping cessation, Oppenheimer maintains a positive outlook on the smoking cessation aspect, which remains the main value driver for the company. The analyst anticipates a New Drug Application (NDA) submission for smoking cessation to occur in the second quarter of 2025.
With these milestones on the horizon, the firm's reiterated Outperform rating and $11 price target reflect confidence in Achieve Life Sciences' trajectory.
The stock currently carries a strong analyst consensus recommendation of 1.12, though investors should note that four analysts have recently revised their earnings expectations downward for the upcoming period.
In addition to the developments in vaping cessation, Oppenheimer maintains a positive outlook on the smoking cessation aspect, which remains the main value driver for the company. The analyst anticipates a New Drug Application (NDA) submission for smoking cessation to occur in the second quarter of 2025.
With these milestones on the horizon, the firm's reiterated Outperform rating and $11 price target reflect confidence in Achieve Life Sciences' trajectory.
The stock currently carries a strong analyst consensus recommendation of 1.12, though investors should note that four analysts have recently revised their earnings expectations downward for the upcoming period.
In addition to the developments in vaping cessation, Oppenheimer maintains a positive outlook on the smoking cessation aspect, which remains the main value driver for the company. The analyst anticipates a New Drug Application (NDA) submission for smoking cessation to occur in the second quarter of 2025.
With these milestones on the horizon, the firm's reiterated Outperform rating and $11 price target reflect confidence in Achieve Life Sciences' trajectory.
In other recent news, Achieve Life Sciences is making significant strides in its fight against nicotine addiction. The company's strategic shift from clinical development to a commercial approach with its smoking cessation drug, cytisinicline, has been a notable development.
A New Drug Application (NDA) for cytisinicline is anticipated in Q2 2025, with the drug potentially becoming the first new prescription smoking cessation aid in nearly two decades.
Rodman & Renshaw recently initiated coverage on Achieve Life Sciences with a Buy rating, highlighting the company's commitment to this global health crisis. The firm also noted the company's exploration of further indications for cytisinicline, including its use for e-cigarette and vaping cessation.
Financially, the company reported a net loss of $12.5 million for Q3 2024 but managed to refinance $20 million in debt. Additionally, plans for a Phase 3 trial for vaping cessation in Q3 2025 and exploration of non-dilutive funding options for future studies were disclosed. These are the recent developments for Achieve Life Sciences, indicating a promising outlook for its endeavors in nicotine addiction treatment.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.